PRMT5

Across TCGA pan-cancer cohorts, PRMT5 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PRMT5 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher PRMT5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRMT5 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

THYM, BRCA, and COAD are the cancer types where PRMT5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
BRCA	OS	Median	All	0.445	0.926	<.001	36	view →
COAD	OS	Median	IV	0.082	0.659	<.001	12	view →
SKCM	OS	Median	All	0.245	0.781	.008	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	All	0.937	0.623	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PRMT5–THYM (OS)

Open the THYM breakdown →